Sinopharm placement succeeds despite tough investment climate

0
1513

Sinopharm Group, the largest distributor of pharmaceutical and healthcare products in China, has raised about US$515 million through its new H-share placement despite difficult market conditions, said a lawyer involved.

周致聪 Charles Chau
周致聪 Charles Chau

“In 2012 and the first quarter of 2013, we witnessed a sharp decline in IPO fund raising in Hong Kong,” Charles Chau, a Hong Kong-based capital markets partner at Morrison & Foerster, told China Business Law Journal.

Morrison & Foerster advised China International Capital Corporation Hong Kong Securities, UBS Hong Kong branch and Morgan Stanley International as placing agents for Sinopharm in this placement. Chau led the law firm’s transaction team.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们